Accelerating norway towards a low-carbon economy — bjørn kjærand haugland, co-founder and CEO, skift.

Bjørn Haugland is the co-founder and Chief Executive Officer of SKIFT Business Climate Leaders (https://www.skiftnorge.no/english), a Norwegian business-led climate initiative with a mission to accelerate the transition to a low-carbon economy and support the government in delivering on its national climate commitments by 2030. The coalition hopes to demonstrate, to businesses and the government, the business potential that exists in the low-carbon economy and help drive the transition.

Mr. Haugland is the former Executive Vice President and the Chief Sustainability Officer in DNV GL Group where he oversaw the groups sustainability performance and drove company-wide sustainability initiatives.

Mr. Haugland has extensive experience assisting multinational companies in areas such as corporate sustainability, innovation and business development. He was responsible for the Global Opportunity Report, a joint initiative together with UN Global Compact and Sustainia, a fact-based sustainability consulting and communication firm.

Mr. Haugland is today a board member at the University of Bergen, WWF, The Peace Research Institute Oslo (PRIO), Sporveien and Kezzler. He is also member of the advisory Board for Centre for Responsible Leadership. He is co-founder of Zeabuz, a new service for urban, emission free, autonomous ferries and Terravera, a tech foundation to make sustainability a reality by giving anyone insights to support their everyday decisions. He is member of the The Norwegian Board of Technology (NBT) that advises the Norwegian Parliament and Government on new technology as well as a member of Norwegian Academy of Technological Sciences.

Mr. Haugland has a M.Sc. in Naval Architecture – Marine Structures and Hydrodynamics, from The Norwegian Institute of Technology and attended the “Strategic International Leadership” program at International Institute for Management Development (IMD) and “Leading Digital Transformation” (INSEAD).

Mr. Haugland is widely recognized in the global debate on sustainability and technology and he has his own blog on the Huffington Post and he is regularly writing articles for Recharge, Teknisk Ukeblad and Sysla Maritime.

International Health Management, Across 17 Countries, 60 Clinics, and 350 Staff — Dr. James Allen, Health Systems Thinkers, LLC.

Dr. James Allen is a primary care internal medicine specialist who developed a fascinating career in international health management and leadership.

Dr. Allen served in the U.S. public health service before moving to Indonesian Borneo in 1994. For the next 22 years he worked in community and occupational health across Asia, managing health teams in 14 countries. As Chevron’s Asia Pacific medical director, he led projects for TB control in Myanmar, primary care in the Philippines, Indonesia, Vietnam, and Bangladesh; and emergency medicine in Azerbaijan and rural China.

After moving to California headquarters in late 2015, Dr. Allen created a global strategy on corporate responsibility for health, establishing a data-based approach in alignment with the Institute for Health Metrics and Evaluation of Seattle. As Chevron’s senior consulting health scientist, he advised social investment teams in Australasia, Central Europe, Latin America, North America, and West Africa. Dr. Allen completed his career at Chevron in 2021 by leading the implementation of Covid-19 management practices for a consortium of oil and gas companies in Angola.

In 2012, Dr. Allen became an adjunct faculty member for the Levinson Institute’s Strategic Leadership for Healthcare Executives, previously affiliated with Harvard Medical School, and now with Pariveda Solutions and Rice University. His education includes a BA from Antioch College, MS from Rensselaer Polytechnic Institute, and his medical degree from Kirksville, MO. He is certified in internal medicine by the American Board of Internal Medicine, and has completed graduate studies in public health, occupational medicine, tropical medicine, toxicology, and healthcare finance and systems management from various institutions – Cornell, the Medical College of Wisconsin, NY Medical College and Singapore Management Institute.

Dr. Allen serves on the Global Advisory Board for the Texas Children’s Hospital HOPE project (Hematology and Oncology Pediatric Excellence), to improve cancer care for children across sub-Saharan Africa. His most recent endeavor is a start-up organization to help corporations and private donors effectively invest in community health in low-resource settings, called Health Systems Thinkers, LLC.

Driver Clocks And Longevity — Dissecting True Functional “Drivers” Of Aging Phenotypes — Dr. Daniel Ives Ph.D., Founder and CEO — Shift Bioscience Ltd.

Dr. Daniel Ives, Ph.D. is Founder and CEO of Shift Bioscience Ltd. (https://shiftbioscience.com), a biotech company making drugs for cellular rejuvenation in humans through the application of machine-learning ‘driver’ clocks to cellular reprogramming, and is the scientific founder who first discovered the gene shifting targets upon which the Shift drug discovery platform is based.

Dr. Ives graduated from Imperial College with a degree in biochemistry and gained his PhD in 2013 working at the MRC Mitochondrial Biology Unit in Cambridge. He carried out his post-doctoral studies under Ian Holt at the National Institute of Medical Research in Mill Hill, now part of the Crick Institute, pursuing damage-removal strategies for mitochondrial DNA mutations.

In 2016 Dr. Ives left the Crick Institute and founded Shift Bioscience to commercialize mitochondrial targeted drugs for age linked diseases, incorporating novel ageing biomarkers technologies, CRISPR screens, and other tools to dissect true functional ‘drivers’ of ageing phenotypes.

Private sector solutions to major social problems — stephanie smith — director, humanitarian & development, mastercard.

Stephanie Smith is a Director, in the Humanitarian & Development group, at Mastercard (https://www.mastercard.us), the American multinational financial services corporation.

Stephanie is responsible for operations of the Humanitarian & Development group at Mastercard, and ensuring the team’s efficient, consistent, and effective delivery against their vision to provide digital tools and access for education, health, commerce, and other critical services for marginalized individuals and communities. The Humanitarian & Development group is focused on driving commercially sustainable social impact in collaboration with governments, NGOs, and other private sector companies.

After graduating from Oxford University, Stephanie began her professional career at a rapidly growing technology company, Applied Predictive Technologies / APT (acquired by Mastercard) delivering analytics software and consulting engagements to Fortune 500s.

Stephanie is particularly passionate about diversity & inclusion and solving social problems, and has experience delivering projects and technologies that drive a lasting social impact.

Stephanie led a pro bono project in partnership with the city government of New Orleans and a non-profit, that pioneered how APT applied data assets and technology to facilitate and measure inclusive growth. Stephanie also proactively took on new projects in social-impact oriented industries (for example, applying Test & Learn analytics to education), and co-led APT’s global Women’s Leadership Network (a business resource group to connect female leaders and build a more inclusive workplace).

Stephanie is also on the Working Group of the Partnership for Central America (https://www.centampartnership.org/) working to support private sector efforts to address the root causes of irregular migration from Central America through coordinated, sustained, and transparent impact across the region.

Stephanie is a passionate mentor of junior staff, and outside of work, volunteers time as a mentor with the Girls Network in London, and fundraising with Girls on the Run in Washington D.C.

Bio-Digital Twins, Quantum Computing, And Precision Medicine — Mr. Kazuhiro Gomi, President and CEO, and Dr. Joe Alexander, MD, Ph.D., Director, Medical and Health Informatics (MEI) Lab, NTT Research.

Mr. Kazuhiro Gomi, is President and CEO of NTT Research (https://ntt-research.com/), a division of The Nippon Telegraph and Telephone Corporation, commonly known as NTT (https://www.global.ntt/), a Japanese telecommunications company headquartered in Tokyo, Japan. Mr. Gomi has been at NTT for more than 30 years and was involved in product management/product development activities at the beginning of his tenure. In September of 2009, Mr. Gomi was first named to the Global Telecoms Business Power100 — a list of the 100 most powerful and influential people in the telecoms industry. He was the CEO of NTT America Inc. from 2010 to 2019 and also served on the Board of Directors at NTT Communications from 2012 to 2019. Mr. Gomi received a Masters of Science in Industrial Engineering from the University of Illinois at Urbana-Champaign, and a Master of Science in Electrical Engineering from Keio University, Tokyo. Mr. Gomi is a member of the board at US Japan Council, a non-profit organization aimed at fostering a better relationship between the US and Japan.

Dr. Joe Alexander, is Director of the Medical and Health Informatics (MEI) Lab at NTT Research, where he oversees the MEI Lab research in multi-scale Precision Cardiology platforms such as the cardiovascular bio-digital twin, as well as heart-on-a-chip technology, specifically aimed at developing the infrastructure for a digital replica of an individual’s heart. In addition, the MEI Lab is working on nano-and micro-scale sensors and electrodes, other organ-on-a-chip micro-fluidics technologies, as well as wearable and remote sensing to support future bio-digital twin applications.

Before coming to NTT Research, Dr. Alexander spent 18 years at Pfizer, Inc., where he had most recently served as Senior Medical Director, Global Medical Affairs, working in cardiovascular medicine, worldwide clinical imaging and measurement technologies, medical devices and pulmonary hypertension, and regularly conducting modeling and simulation research in many of these areas. He previously worked for two years at Merck, Inc. and spent eight years at Vanderbilt University, where he completed a two-year residency in internal medicine and served as a professor of medicine and biomedical engineering. Dr. Alexander obtained his M.D. and Ph.D. (in biomedical engineering) degrees at the Johns Hopkins University School of Medicine.

Making Power Wheelchair Technologies “Smarter” — Barry Dean, CEO, LUCI

Barry Dean is an award-winning songwriter turned smart wheelchair technology company founder.

As CEO of LUCI (https://luci.com/), a company re-imagining mobility for power wheelchairs, Barry sets the strategic vision and leads the company towards its goal of providing security, stability and connectivity for power wheelchairs. He founded the company with his brother, Jered, in 2017 with hopes of building a smarter solution for his daughter Katherine and all power wheelchair riders.

Barry has written multiple No. 1 singles including “Pontoon” (Little Big Town), “Day Drinking” (Little Big Town), ” Somebody’s Daughter” (Tenille Townes), and “Think a Little Less” (Michael Ray), along with a Top 40 hit with “Girls Chase Boys” (Ingrid Michaelson). He has been nominated for a Grammy for Best Country Song on Tim McGraw’s “Diamond Rings and Old Barstools.”

Barry is a founding writer at Creative Nation Music, Recording Academy (GRAMMY) Nashville Chapter Governor, and has previously served two terms as a board member of the Nashville Songwriters Association International. Prior to becoming a songwriter, he led market strategy and product development for a leading education technology company.

Barry currently lives in Nashville, Tenn.

The science and technology of growing young — sergey young, founder, longevity vision fund.

Sergey Young (https://sergeyyoung.com/) is a longevity investor, visionary, and author, with a mission to help one billion people extend their healthy lifespans by making longevity affordable and accessible for everyone. As part of this mission, he is the Founder of the Longevity Vision Fund (LVF — https://lvf.vc/), a $100 Million venture capital fund that invests in technologies with the potential to disrupt life sciences and healthcare to help people live longer and healthier lives.

Sergey’s investment experience, spanning over 20 years, includes managing a $2 Billion private equity fund and co-founding Peak State Ventures, a New York-based private equity fund focusing on new technologies in Real Estate, Digital Healthcare, and the Future of Work. Sergey is also Longevity Venture Partner at BOLD Capital Partners, a $250 Million fund focusing on exponential technologies co-founded by Peter Diamandis.

Sergey’s longevity-related activities also include the following:

- Innovation Board Member at XPRIZE Foundation, dedicated to solving the world’s biggest problems;
- Development Sponsor of Age Reversal XPRIZE, a global initiative designed to incentivize the development of technological breakthroughs to cure aging;
- Board of Directors of American Federation of Aging Research (AFAR);

- Financial Advisory Board Member at All-Party Parliamentary Group (APPG) for Longevity, helping to shape national longevity strategy in the UK.

Sergey is also the author of an upcoming book, “The Science and Technology of Growing Young”. (https://www.amazon.com/Science-Technology-Growing-Young-Brea…atfound-20)

Improving Quality Of Life & Health, For Hundreds Of Millions Globally, Suffering Food Allergies & Intolerances — Lisa Gable, Chief Executive Officer, Food Allergy Research & Education (FARE)

Lisa Gable is the Chief Executive Officer, of Food Allergy Research & Education (FARE — https://www.foodallergy.org), an organization with a mission to improve the quality of life and the health of 85 million Americans with food allergies and food intolerances, including 32 million of those are at risk for life-threatening anaphylaxis, and to provide them hope through the promise of new treatments. To date FARE has turned over $100 million in donor gifts into ground-breaking research and has provided a voice for the community, advocating on its behalf and offering hope for a better tomorrow.

Ms. Gable has served four U.S. presidents and two governors, counseled Fortune 500 CEOs, and represented global public-private partnerships and non-profits with an end goal of moving organizations to higher levels of performance.

As the former President of the Healthy Weight Commitment Foundation, Ms. Gable created and led a coalition of food and beverage industry corporations and public health and government agencies, resulting in the reduction of 6.4 trillion calories from the American diet.

Ms Gable was appointed the first female U.S. Commissioner General to the 2005 Aichi World EXPO, holding the personal rank of Ambassador, served as a U.S. Delegate to the United Nations Commission on the Status of Women, and served both in the Reagan White House and Defense Department, serving as an advisor to the Secretary of Defense and the Joint Chief of Staff.

Ms. Gable’s corporate experience included serving as senior vice president of Global Public Policy at PepsiCo, and 15 years in Silicon Valley, including Global Brand Identity Manager for Intel Corporation, as Intel was on the cusp of launching what would become one of the most dominant tech brands, Intel Inside.

Among her varied volunteer activities, Ms. Gable has served on several boards including as a National Trustee for the Boys and Girls Club of America, a board member for Girl Scouts of the USA and as a member of the Institute of Medicine Roundtable on Obesity Solutions. A published writer, her new book Turnaround: How to Change Course When Things Are Going South (https://turnaroundbook.com/) will be coming out October 5, 2021.

Ms. Gable also has had recurring media appearances including four years as a regularly scheduled guest with Lifetime’s national morning program The Balancing Act.

Mitochondrial Quality Control (Mitophagy), CNS Disorders, and Aging — Dr. Spring Behrouz, Ph.D., CEO, Vincere Biosciences Inc. / CEO, Neuroinitiative LLC.

Dr. Bahareh (Spring) Behrouz, PhD, is the CEO of Vincere Biosciences Inc (https://vincerebio.com/), a biotech company focused on developing novel, small molecule therapeutics targeting mitochondrial pathways and the improvement of mitochondrial quality.

Dr. Behrouz is also the CEO of NeuroInitiative, LLC (https://www.neuroinitiative.com/), a computational biology company she co-founded in 2014, which develops simulations of disease using their patented software platform. A core focus of her research at NeuroInitiative is on the elucidation of complex, converging pathways that contribute to the pathogenesis of Parkinson’s disease (PD), a neuro-degenerative brain disorder which dramatically effects movement, which nearly one million people in the U.S. are living with, and 10 million patients worldwide.

Dr. Behrouz received her graduate training at Michigan State University in the laboratory of Dr. John Goudreau and studied differential susceptibility of dopaminergic neuron sub-types in models of PD. She completed her post-doctoral training in the laboratory of Dr. Matthew Farrer at the Mayo Clinic in Jacksonville, where she primarily focused on in-vivo and primary culture models of LRRK2-mediated pathogenesis and was part of the team that discovered a new pathogenic mutation in VPS35.

Replacing Aging — Dr. Jean M. Hebert, Ph.D. Albert Einstein College of Medicine.

Dr. Jean M. Hebert, Ph.D. (https://einsteinmed.org/faculty/9069/jean-hebert/) is Professor in the Department of Genetics and in the Dominick P. Purpura Department of Neuroscience, at Albert Einstein College of Medicine.

He’s also the author of the book Replacing Aging, which describes how regenerative medicine will beat aging.

With a Ph.D. in Genetics from the University of California, San Francisco, Dr. Hebert’s current lab’s projects fall into two groups.

First, they focus on using the mouse neocortex as a platform for testing the ability of multi-cell type grafts (increasingly resembling normal neocortex) to integrate with host tissue.

Secondly, they are testing the ability of genetically engineered microglia that disperse throughout the adult neocortex to bolster neocortical function.

These highly collaborative projects require a range of multidisciplinary methods, including molecular genetics, human embryonic stem cell biology, transcriptomics, surgery, electrophysiology, live brain imaging, and behavioral tests, among others.